Debiopharm and BIOASTER join forces against infectious diseases

Debiopharm and BIOASTER join forces against infectious diseases The Swiss biopharmaceutical company Debiopharm and BIOASTER, the French Technology Research Institute in infectiology have officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. This relationship will harness BIOASTER’s scientific and technical expertise, including technology platforms,…..

Trend Chart on Innovative Biotherapies 26th April

FEATURE STORY ● A safe and potent anti-CD19 CAR T cell therapy GENE THERAPY ●Chimeric antigen receptor T cell persistence and memory cell formation DISRUPTIVE TECHNOLOGIES  ●Hemophilia A : Restoration of FVIII expression by targeted gene insertion in the FVIII CLINICAL TRIALS-DATA  ● Avexis data reinforce effectiveness of Zolgnesma® in treating…..

A new gene and cell therapy production facility in Maryland

A new gene and cell therapy production facility in Maryland Precigen's new manufacturing facility has officially opened its doors in Germantown, Maryland. The wholly-owned subsidiary of Intrexon commenced the build-out of the nearly 5,000 square foot manufacturing facility in 2018 to support gene therapy manufacturing. The good manufacturing practices (GMP) facility…..

Waylivra™ (volanesorsen), first therapy for familial chylomicronemia syndrome

Waylivra™ (volanesorsen), first therapy for familial chylomicronemia syndrome The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for Waylivra™ (volanesorsen) for the treatment of familial chylomicronemia syndrome (FCS). This antisense oligonucleotide developped by Ionis Pharmaceuticals and its affiliate Akcea…..

First European Market Approval for Nanobiotix

First European Market Approval for Nanobiotix The French nanomedicine company Nanobiotix has received its first European market approval (CE mark) enabling commercialisation of its lead product Hensify® (NBTXR3) in the 27 EU countries  for the treatment of locally advanced soft tissue sarcoma. “We could not be more proud to receive market approval…..

1eres Journées Polepharma de microbiomique

1eres Journées Polepharma de microbiomique Le cluster de production pharmaceutique Polepharma organise ses premières journées de microbiomique les 9 et 10 avril prochains à l'UFR Santé de l'université de Rouen. Le programme a été co-construit entre académiques, start-up, PME et grands industriels de la pharma présents au sein du premier…..

Imabiotech boosts its strategic partnerships

Imabiotech, a French CRO based in Lille (France) and in Boston (USA), is expanding its range of services. This company is offering innovative imaging services and software to the pharmaceutical research sector.  These services are based on histology combined to label free molecular imaging (Quantitative Mass Spectrometry Imaging, QMSI) . This technology…..


RNA science is now translated into new therapies… Last August, the FDA approved the first RNAi therapy, Onpattro®… RNA drugs allow precised silencing or activation of genes… RNA drugs can address a wide range of common and rare diseases… More than 60 rare or common diseases are currently  targeted….  BioPharmAnalyses…..

EMA’s Regulatory Science to 2025 Strategy

The European Medicine Agency (EMA) is launching a six-month public consultation on its draft ‘ Regulatory Science to 2025’ strategy  for a six-month public consultation. This  sixty-page document proposes the plan for advancing the Agency’s engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines. The…..